Oral glutamine protects against cyclophosphamide-induced cardiotoxicity in experimental rats through increase of cardiac glutathione

Nutrition

Volumn 25, Issue 7-8, 2009, Pages 812-817

  Todorova, Valentina ^a   Vanderpool, Doug ^a   Blossom, Sarah ^a   Nwokedi, Emmanuel ^a   Hennings, Leah ^a   Mrak, Robert ^a   Klimberg, V Suzanne ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Cardiotoxicity; Cyclophosphamide; Glutamine; Glutathione; Heart

Indexed keywords

AMINO ACID; CYCLOPHOSPHAMIDE; GLUTAMINE; GLUTATHIONE; GLYCINE; SODIUM CHLORIDE;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CARDIOTOXICITY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; FEEDING; GLUTATHIONE METABOLISM; HEART; HEART INJURY; HEART MUSCLE NECROSIS; HEART PROTECTION; HISTOPATHOLOGY; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; SURVIVAL; UPREGULATION;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CYCLOPHOSPHAMIDE; DISEASE MODELS, ANIMAL; GLUTAMINE; GLUTATHIONE; GLYCINE; HEART DISEASES; MALE; MUSCLE CELLS; MYOCARDIUM; NECROSIS; RANDOM ALLOCATION; RATS; RATS, INBRED F344;

RATTUS;

EID: 67349280855     PISSN: 08999007     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nut.2009.01.004     Document Type: Article

References (44)

1. Gershwin M.E., Goetzl E.J., and Steinberg A.D. Cyclophosphamide: use in practice. Ann Intern Med 80 (1974) 531
2. Tew K., Colvin O.M., and Chabner B.A. Alkylating agents. In: Chabner B.A., and Longo D.L. (Eds). Cancer chemotherapy and biotherapy: principles and practice. 2nd ed. (1996), Lippincott-Raven, Philadelphia
3. Gottdiener J.S., Applebaum E.R., Ferrans V.J., Deisseroth A., and Ziegler J. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med 141 (1981) 758-763
4. Birchall I.W., Lalani Z., Venner P., and Hugh J. Fatal haemorrhagic myocarditis secondary to cyclophosphamide therapy. Br J Radiol 73 (2000) 1112-1114
5. Kamezaki K., Fukuda T., Makino S., and Harada M. Cyclophosphamide induced cardiomyopathy in a patient with seminoma and a history of mediastinal irradiation. Intern Med 44 (2005) 120-123
6. Brockstein B.E., Smiley C., Al-Sadir J., and Williams S.F. Cardiac and pulmonary toxicity in patients undergoing high-dose chemotherapy for lymphoma and breast cancer: prognostic factors. Bone Marrow Transplant 25 (2000) 885-894
7. Taniguchi I. Clinical significance of cyclophosphamide-induced cardiotoxicity. Intern Med 44 (2005) 123-135
8. Nieto Y., Cagnoni P.J., Bearman S.I., et al. Cardiac toxicity following high-dose cyclophosphamide, cisplatin, and BCNU (STAMP-I) for breast cancer. Biol Blood Marrow Transplant 6 (2000) 198-3
9. Appelbaum F.R., Strauchen J.A., Graw R.G., et al. Acute lethal carditis caused by high-dose combination chemotherapy: a unique clinical and pathological entity. Lancet 1 (1976) 58-62
10. Goldberg M.A., Antin J.H., Guinan E.C., and Rappeport J.M. Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood 68 (1986) 1114-1118
11. Fleming R.A. An overview of cyclophosphamide and isosfamide pharmacology. Pharmacotherapy 17 (1997) 146S-154
12. Huang Z., and Waxman D.J. Modulation of cyclophosphamide-based cytochrome P450 gene therapy using liver P450 inhibitors. Cancer Gene Ther 8 (2001) 450-458
13. Slavin R.E., Millan J.C., and Mullins G.M. Pathology of high dose intermittent cyclophosphamide therapy. Hum Pathol (1975) 693-709
14. Patel J.M., and Block E.R. Cyclophosphamide-induced depression of the antioxidant defense mechanisms of the lung. Exp Lung Res 8 (1985) 153-165
15. Patel J.M. Stimulation of cyclophosphamide-induced pulmonary microsomal lipid peroxidation by oxygen. Toxicology 45 (1987) 79-91
16. Dorr R.T., and Lagel K. Effect of sulfhydryl compounds and glutathione depletion on rat heart myocyte toxicity induced by 4-hydroperoxycyclophosphamide and acrolein in vitro. Chem Biol Interact 93 (1994) 117-128
17. Sudharsan P.T., Mythili Y., Selvakumar E., and Varalakshmi P. Lupeol and its ester meliorate the cyclophosphamide provoked cardiac lysosomal damage studied in rat. Mol Cell Biochem 282 (2006) 39-44
18. Manda K., and Bhatia A.L. Prophylactic action of melatonin against cyclophosphamide-induced oxidative stress in mice. Cell Biol Toxicol 19 (2003) 367-372
19. Singh D.K., and Lippman S.M. Cancer chemoprevention part 1: retinoids and carotenoids and other classic antioxidants. Oncology 12 (1998) 1643-1660
20. Klimberg V.S. Glutamine, cancer and its therapy. Am J Surg 172 (1996) 418-424
21. Welbourne T. Ammonia production and glutamine incorporation into glutathione in the functioning rat kidney. Can J Biochem 57 (1979) 233-237
22. Sacks G.S. Glutamine supplementation in catabolic patients. Ann Pharmacother 33 (1999) 348-354
23. Bernt E., and Bergmeyer H.U. L-Glutamate UV-assay with glutamate dehydrogenase and NAD. In: Bergmeyer H.U. (Ed). Methods of enzymatic analysis. 2nd English ed. Volume 4 (1974), Verlag-Chemie International, Deerfield Beach, FL 1704-1708
24. Nahorski S.R. Fluorometric measurement of glutamine and asparagine using enzymic methods. Anal Biochem 42 (1971) 136-142
25. Tietze F. Enzymatic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Ann Biochem 27 (1969) 502-522
26. Anderson M.E. Enzymatic and chemical methods for the determination of glutathione. In: Dolphin D. (Ed). Glutathione Volume 1 (1983), John Wiley & Sons, New York 340-365
27. Griffith O.W. Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine. Anal Biochem 106 (1980) 207-212
28. Mitchell J.B., and Russo A. The role of glutathione in radiation and drug induced cytotoxicity. Br J Cancer 8 suppl (1987) 96S-104
29. Schafer F.Q., and Buettner G.R. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic Biol Med 30 (2001) 1191-1212
30. Friezen C., Kiess Y., and Debatin K.M. A critical role of glutathione in determining apoptosis sensitivity and resistance in leukemia cells. Cell Death Differ 11 suppl 1 (2004) S73-S85
31. Tormos C., Javier Chaves F., Garcia M.J., Garrido F., Jover R., O'Connor J.E., et al. Role of glutathione in the induction of apoptosis and c-fos and c-jun mRNAs by oxidative stress in tumor cells. Cancer Lett 208 (2004) 103-113
32. Perchellet J.P., Owen M.D., Posey T.D., Orten D.K., and Schneider B.A. Inhibitory effects of glutathione level-raising agents and D-alpha-tocopherol on ornithine decarboxylase induction and mouse skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate. Carcinogenesis 6 (1985) 567-57
33. Baruchel S., Wang T., Farah R., Jamali M., and Batist G. In vivo selective modulation of tissue glutathione in a rat mammary carcinoma model. Biochem Pharmacol 50 (1995) 1505-1508
34. Wang T., Chen X., Schecter R.L., Baruchel S., Alaoui-Lamali M., Melnychuk D., and Batist G. Modulation of glutathione by a cysteine pro-drug enhances in vivo tumor response. J Pharamacol Exp Ther 276 (1996) 1169-1173
35. Chen K., Nezu R., Sando K., Haque S.M., Iiboshi Y., Masunari A., et al. Influence of glutamine-supplemented parenteral nutrition on intestinal amino acid metabolism in rats after small bowel resection. Surg Today 26 (1996) 618-623
36. O'Riordain M.G., De Beaux A., and Fearon K.C. Effect of glutamine on immune function in the surgical patient. Nutrition 12 suppl (1996) S82-S84
37. Luo M., Fernandez-Estivariz C., Jones D.P., Accardi C.R., Alteheld B., Bazargan N., et al. Depletion of plasma antioxidants in surgical intensive care unit patients requiring parenteral feeding: effects of parenteral nutrition with or without alanyl-glutamine dipeptide supplementation. Nutrition 24 (2008) 37-44
38. Rubio I.T., Cao Y., Hutchins L., Westbrook K.C., and Klimberg V.S. Effect of glutamine on methotrexate efficacy and toxicity. Ann Surg 227 (1998) 772-780
39. Jaakkola K., Lahteenmaki P., Laakso J., et al. Treatment with antioxidant and other nutrients in combination with chemotherapy and irradiation in patients with small-cell lung cancer. Anticancer Res 12 (1992) 599-606
40. Whelan R.L., Horvath K.D., Gleason N.R., et al. Vitamin and calcium supplement use is associated with decrease adenoma recurrence in patients with a previous history of neoplasia. Dis Colon Rectum 42 (1999) 212-217
41. Lamm D.L., Riggs D.R., Shriver J.S., et al. Megadose vitamins in bladder cancer: a double-blind clinical trial. J Urol 151 (1994) 21-26
42. Wagdi P., Fluri M., Aeschbacher B., et al. Cardioprotection in patients undergoing chemo- and/or radiotherapy for neoplastic disease. Jpn Heart J 37 (1996) 353-359
43. Lamson D.W., and Matthew S. Brignall MS. Antioxidants in cancer therapy; their actions and interactions with oncologic therapies, Altern Med Rev 4 (1999) 304-329
44. Conklin K.A. Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. Integr Cancer Ther 3 (2004) 294-300